Recurrent Glioblastoma-Molecular Underpinnings and Evolving Treatment Paradigms.

Autor: Chang C; Warren Alpert Medical School, Brown University, Providence, RI 02912, USA., Chavarro VS; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA., Gerstl JVE; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA., Blitz SE; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.; Harvard Medical School, Harvard University, Boston, MA 02115, USA., Spanehl L; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Neurosurgery, University of Rostock, 18055 Rostock, Germany., Dubinski D; Department of Neurosurgery, University of Rostock, 18055 Rostock, Germany., Valdes PA; Department of Neurosurgery, University of Texas Medical Branch, Galveston, TX 77555, USA., Tran LN; Division of Biology and Medicine, Brown University, Providence, RI 02912, USA., Gupta S; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.; Harvard Medical School, Harvard University, Boston, MA 02115, USA., Esposito L; Department of Medicine and Surgery, Unicamillus University, 00131 Rome, Italy., Mazzetti D; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA., Gessler FA; Department of Neurosurgery, University of Rostock, 18055 Rostock, Germany., Arnaout O; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.; Harvard Medical School, Harvard University, Boston, MA 02115, USA., Smith TR; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.; Harvard Medical School, Harvard University, Boston, MA 02115, USA., Friedman GK; Division of Pediatrics, Neuro-Oncology Section, MD Anderson Cancer Center, Houston, TX 77030, USA., Peruzzi P; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.; Harvard Medical School, Harvard University, Boston, MA 02115, USA., Bernstock JD; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.; Harvard Medical School, Harvard University, Boston, MA 02115, USA.; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 19; Vol. 25 (12). Date of Electronic Publication: 2024 Jun 19.
DOI: 10.3390/ijms25126733
Abstrakt: Glioblastoma is the most common and lethal central nervous system malignancy with a median survival after progression of only 6-9 months. Major biochemical mechanisms implicated in glioblastoma recurrence include aberrant molecular pathways, a recurrence-inducing tumor microenvironment, and epigenetic modifications. Contemporary standard-of-care (surgery, radiation, chemotherapy, and tumor treating fields) helps to control the primary tumor but rarely prevents relapse. Cytoreductive treatment such as surgery has shown benefits in recurrent glioblastoma; however, its use remains controversial. Several innovative treatments are emerging for recurrent glioblastoma, including checkpoint inhibitors, chimeric antigen receptor T cell therapy, oncolytic virotherapy, nanoparticle delivery, laser interstitial thermal therapy, and photodynamic therapy. This review seeks to provide readers with an overview of (1) recent discoveries in the molecular basis of recurrence; (2) the role of surgery in treating recurrence; and (3) novel treatment paradigms emerging for recurrent glioblastoma.
Databáze: MEDLINE